James N. Ingle

TL;DR: This initial discovery genome-wide association study identified common single-nucleotide polymorphisms (SNP) in or near the ZNF423 and CTSO genes that were associated with breast cancer risk during SERM therapy and showed that both ZNF422 and C TSO participated in the estrogen-dependent induction of BRCA1 expression.

TL;DR: Estrogen suppression induced by letrozole was substantial despite the concomitant administration of TAM, and the antitumor effect of TAM plus letroZole was less than expected.

TL;DR: Patients originally randomly assigned to receive letrozole within 3 months of stopping tamoxifen did better than placebo patients in DFS and CLBC, despite 66% of placebo patients taking letroZole after unblinding.

TL;DR: It is apparent that, while some slight advantage does occur for that group of patients receiving initial polychemotherapy, the magnitude of this effect is not great and is short in duration, and serious consideration should be given to the assessment of new agents as first-line therapy.

TL;DR: The key role of NOTCH3 oncogenic signaling in the genesis of breast cancer metastasis is demonstrated and provided a compelling preclinical rationale for the design of novel therapeutic strategies that will selectively target NotCH3 to halt metastatic seeding and to improve the clinical outcomes of patients with breast cancer.